Does Periprocedural Nicorandil Improve Cardiovascular Outcomes in Acute Myocardial Infarction? - Meta-Analysis

BACKGROUND in conjunction with Percutaneous Coronary Intervention (PCI) has shown to improve the coronary reflow. It is not if use of Nicorandil could lead to improvement in short and long-term cardiovascular outcomes. AND METHODS evaluation was done to determine the efficacy of Nicorandil in improving the cardiovascular outcomes in Acute Infarction (AMI) patients in the setting of PCI. The search terms used were Nicorandil and AMI and PCI using and Science Direct. Design- A systematic review and meta-analysis. randomised clinical trials were identified. Nicorandil significantly reduced in-hospital outcomes (RD: 0.16; 95%, CI: - 0.23 to -0.09; I 2 : 95%; p<0.00001; FE model). There was a reduction in the number of patients with thrombolysis in myocardial (TIMI flow ≤2) grade (RD: 0.06; 95%, CI: -0.09 to -0.02; I 2 : 95%; p=0.002; FE model). There was no significant in the major adverse cardiovascular events between Nicorandil and controls when assessed between 30 days to 8 after discharge. Nicorandil clearly appears to have a benefit in improving in-hospital cardiovascular outcomes, it remains to be seen if could translate into improved long-term cardiovascular outcomes.